Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): Shares surge 13% on $15.2B BMS deal

Jiangsu Hengrui Pharmaceuticals, China's largest drug company by market capitalization, has entered a global collaboration and licensing agreement with U.S. pharmaceutical giant Bristol Myers Squibb (BMS) valued at up to $15.2 billion. The deal, announced on May 12, 2026, covers four oncology and hematology programs from Hengrui, four immunology assets from BMS, and five novel programs for joint development. Hengrui's Hong Kong-traded shares (01276.HK) surged as much as 13% to HK$76.75, outperforming the Hang Seng index, according to Investing.com as of 05/12/2026. BMS will pay up to $950 million in near-term payments, including a $600 million upfront.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Jiangsu Hengrui Pharmaceuticals: core business model

Jiangsu Hengrui Pharmaceuticals focuses on research, development, manufacturing, and sales of pharmaceuticals, particularly in oncology, anti-infectives, surgery, and metabolic diseases. As China's top drug maker by market cap, it invests heavily in innovative therapies, with a pipeline emphasizing small-molecule drugs and biologics. The company operates dual listings on the Shenzhen Stock Exchange (600276.SS) and Hong Kong Exchange (01276.HK), providing access for international investors.

Main revenue and product drivers for Jiangsu Hengrui Pharmaceuticals

Key revenue comes from marketed oncology drugs like camrelizumab and pyrotinib, alongside a robust pipeline of preclinical and clinical assets. Licensing deals, such as the recent BMS partnership, bolster near-term cash flow through upfronts and milestones. In 2025 full-year results published in early 2026, Hengrui reported strong growth in innovative drug sales, according to company filings.

Industry trends and competitive position

The global oncology market is projected to exceed $300 billion by 2028, driven by immunotherapy and targeted therapies, per Citeline as of 05/12/2026. Hengrui competes with global leaders like BMS while dominating China's innovative drug segment, leveraging cost advantages and regulatory support for domestic R&D.

Why Jiangsu Hengrui Pharmaceuticals matters for US investors

With its BMS partnership, Hengrui gains U.S. market exposure via a major American pharma, relevant for US investors tracking China biotech growth. The deal highlights cross-border pharma ties, potentially influencing ADRs or ETFs with Chinese exposure. Hengrui's preclinical assets could yield royalties on U.S. sales, tying its performance to American oncology demand.

Conclusion

The BMS deal marks a milestone for Jiangsu Hengrui Pharmaceuticals, providing substantial upfront funding and milestone potential amid a surging share price. While preclinical stages carry development risks, the partnership validates Hengrui's R&D capabilities and opens global doors, particularly relevant for US investors eyeing China pharma plays. Market reactions reflect optimism, but execution on milestones will shape future performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.